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DNA vaccines expressing the envelope glycoprotein (GP) or nucleocapsid protein (NP) genes of Ebola virus were evaluated
in adult, immunocompetent mice. The vaccines were delivered into the skin by particle bombardment of DNA-coated gold
beads with the PowderJect-XR gene gun. Both vaccines elicited antibody responses as measured by ELISA and elicited
cytotoxic T cell responses as measured by chromium release assays. From one to four vaccinations with 0.5 mg of the GP
DNA vaccine resulted in a dose-dependent protection from Ebola virus challenge. Maximal protection (78% survival) was
achieved after four vaccinations. Mice were completely protected with a priming dose of 0.5 mg of GP DNA followed by three
or four subsequent vaccinations with 1.5 mg of DNA. Partial protection could be observed for at least 9 months after three
immunizations with 0.5 mg of the GP DNA vaccine. Comparing the GP and NP vaccines indicated that approximately the same
level of protection could be achieved with either vaccine.
INTRODUCTION
Ebola virus (EBOV), a member of the family Filoviridae,
causes severe viral hemorrhagic fever and high mortality
in humans. The ecology and epidemiology of EBOV are
poorly understood and the host species that maintains
the virus in nature is unknown. Although aerosol trans-
mission of EBOV was demonstrated in primates (Jaax et
al., 1995), most nosocomial or human-to-human trans-
mission has been correlated with direct contact with
infected patients or their bodily fluids (Peters et al., 1994;
Feldmann and Klenk, 1996). To date, three distinct EBOV
strains have been found to be pathogenic for humans:
Zaire, Sudan, and Ivory Coast (Peters et al., 1994; Le
Guenno et al., 1995). A fourth strain, Reston, appears to
be nonpathogenic for humans but causes hemorrhagic
fever in nonhuman primates (Jahrling et al., 1990).
EBOV caused two major outbreaks of Ebola hemor-
rhagic fever (EHF), in 1976 and 1995, during which hun-
dreds of cases were reported, with mortality rates of
approximately 80–90% (CDC, 1995a,b; Peters et al., 1994).
EBOV isolates from these outbreaks were antigenically
and genetically very similar; thus the same virus was
responsible for both epidemics (Sanchez et al., 1996).
EBOV particles consist of helical nucleocapsids con-
taining approximately 19 kb of single-strand, negative-
sense RNA. The ribonucleocapsids are surrounded by a
membrane of host origin from which a highly glycosy-
lated type 1 transmembrane protein (GP) protrudes (Feld-
mann et al., 1994; Buchmeier et al., 1983; Sanchez et al.,
1993; Kiley et al., 1980, 1988; Geisbert and Jahrling, 1990).
The EBOV genome encodes seven proteins with a gene
order of NP-VP35-VP40-GP-VP30-VP24-L (Elliott et al.,
1993; Sanchez et al., 1993). Each product is produced
from a separate, polyadenylated mRNA. GP is encoded
in two adjoining reading frames which are connected by
transcriptional editing. The editing involves inserting a
nontemplated adenosine into a stretch of seven aden-
osines in the mRNA (Sanchez et al., 1996). In addition to
GP, VP 24, a minor envelope protein, is associated with
virions. The helical ribonucleocapsids contain four of the
viral proteins: NP, the major nucleocapsid protein; L, an
RNA-dependent RNA polymerase; VP30; and VP35. The
roles of these latter two proteins are not clearly defined,
but by analogy to Marburg virus (MBGV) and to viruses in
the Paramyxoviridae family, they may be involved in reg-
ulation of gene expression or replication. VP40 is the
matrix protein, which permits interaction between mem-
brane components and NP (Sanchez et al., 1993).
Currently, no effective vaccines or therapies for EHF
have been reported. Conventional approaches to vac-
cine development, such as inactivation or attenuation of
virulent viruses, pose risks to researchers, manufactur-
ers, and recipients of such vaccines. Recombinant DNA
approaches offer means to eliminate the risk associated
with production of the vaccines as well as the risk of
incomplete inactivation or reversion to wild-type virus.
The naked DNA approach has proven to be a simple and
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effective means for generating protective immunity to a
variety of pathogens in a number of animal models (e.g.,
Fuller and Haynes, 1994; Fynan et al., 1993, 1995; Pert-
mer et al., 1995; Schmaljohn et al., 1997; Ulmer et al.,
1995, 1996a,b; Whalen, 1996). One major advantage of
this approach, compared to the use of inactivated or
preformed subunit vaccines, is that the foreign genes are
transcribed within the host’s own cells; thus, they mimic
natural infection, resulting in both cell-mediated and hu-
moral immune responses (Eisenbraun et al., 1993; Fynan
et al., 1993; Haynes et al., 1994; Pertmer et al., 1995).
Gene gun immunization permits the use of very small
amounts of DNA because the DNA is delivered directly
into host cells rather than into intercellular spaces. More-
over, the site of gene gun inoculation, the skin, is an
immunologically active tissue (Stingl, 1993), and the po-
tential for direct delivery of DNA into antigen presenting
cells (i.e., dendritic cells) is present (Condon et al., 1996).
Although immune mechanisms for preventing and
clearing filovirus infections are not well understood,
there appears to be some association between the pres-
ence of neutralizing antibody and protection. Passive
transfer of hyperimmune guinea pig sera was demon-
strated to protect guinea pigs from challenge with MBGV
(Hevey et al., 1997). Similarly, passive transfer of equine
IgG to EBOV protected guinea pigs (Jahrling et al., 1996)
and baboons (Mikhailov et al., 1994) from a subsequent
EBOV challenge. However, passive transfer of the same
sera to cynomolgus monkeys did not afford protection
(Jahrling et al., 1996). It was suggested that because
cynomolgus monkeys develop higher viremias than ba-
boons, it was not possible to overcome the viral load with
the transferred antibody (Jahrling et al., 1996). Thus, elic-
itation of neutralizing antibody to EBOV appears to be a
desirable objective for a vaccine, but it may not be
sufficient for protection and may not even be the primary
means of protection.
EBOV GP is the most likely viral protein to elicit neu-
tralizing antibodies, because it is the only protein known
to be on the virion surface. Also, monoclonal antibodies
to GP of MBGV were found to neutralize infectious virus
in cell culture assays (A. Schmaljohn, unpublished data).
GP is also a reasonable candidate for a subunit vaccine,
as demonstrated with baculovirus-expressed MBGV GP
(Hevey et al., 1997) and vaccinia virus-expressed EBOV
GP (Gilligan et al., 1997), both of which were able to elicit
partially protective immune responses in guinea pigs. If
a strong cell-mediated immune response is also needed
for effective protection from filovirus infections, then
other proteins such as NP may also prove useful.
In the studies reported here, we examined the poten-
tial of the GP and NP genes of EBOV to elicit protective
immunity. An adult mouse model recently developed and
described (Bray et al., 1996, 1998) was used in lieu of
guinea pigs in order to more easily achieve significant
group sizes in a restrictive BSL4 environment and to
facilitate analyses of cellular immune mechanisms.
RESULTS
Cloning and sequence analysis of the EBOV GP
and NP genes
Two different EBOV, strain Zaire 95, GP genes were
generated by RT–PCR. One of the cDNAs encompassed
only the coding region of the GP gene and the other
included an additional 139 nucleotides of 59 noncoding
information. The latter construct was produced so that
we could determine if the noncoding sequences, which
form a potential stem-loop structure (Sanchez et al.,
1993), might influence expression of GP in our system.
Both cDNAs were cloned into the plasmid vector pCRII
and later were subcloned into the plasmid vector
pWRG7077. Our GP gene sequences differed from that
reported previously for EBOV, strain Zaire 1995 (GenBank
Accession No. U28077), at only 5 nucleotides. Four of the
nucleotide differences resulted in substitutions of pre-
dicted amino acids (E 3 D at position 93; S 3 T at
position 355; G3 A at position 415; and F3 I at position
601 with respect to the methionine initiation codon for
EBOV GP). As reported previously (Sanchez et al., 1993,
1996; Volchkov et al., 1995), the complete GP of EBOV is
encoded in a reading frame that is generated by tran-
scriptional editing. The editing involves inserting a non-
templated adenosine into a stretch of seven other tem-
plated adenosines. By sequencing numerous clones, we
found that there was a great variation in the number of A
residues at the transcriptional editing site, with as few as
4 A residues to as many as .50 residues. We did not
determine if this observation was related to reverse
transcription or PCR artifacts or if in fact the viral RNA
population varied this extensively. We selected two of the
clones with the correct number of A residues (8) for
further analysis of GP expression.
The NP gene of EBOV was produced by RT–PCR,
cloned into the plasmid pCRII, and then subcloned into
pWRG7077. The gene was sequenced and compared to
that previously reported for a 1976 isolate of EBOV
(Sanchez et al., 1993; GenBank Accession No. L11365).
The sequences differed by 35 of 2220 nucleotides and in
8 of 739 predicted amino acids. We deposited the NP
nucleotide sequence from this 1995 EBOV isolate in
GenBank as AF054908.
Transient expression of the GP and NP genes
Transient expression was assayed for the two EBOV
GP genes and the NP gene which were cloned into pCRII
and pWRG7077 vectors. The expression assay for the
pCRII constructs employed a recombinant vaccinia virus
expressing T7 polymerase for transcription of the gene.
The expression assay for the pWRG7077 constructs re-
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lied on recognition of the cytomegalovirus immediate
early promoter in the plasmid by a host cell polymerase.
Expression products from both assay systems were ra-
diolabeled, immune-precipitated with antibodies to
EBOV, and then were compared by SDS–polyacrylamide
gel electrophoresis. As reported for authentic EBOV (El-
liott et al., 1985), the expressed GP had an apparent
molecular weight approximately twice that predicted
from the amino acid sequence. This discrepancy is due
to the extensive O- and N-linked glycosylation of the
gene product (Feldmann et al., 1994, 1991; Sanchez et al.,
1993). The GP gene products often appeared as dou-
blets, which may reflect either differentially glycosylated
forms of GP or some other posttranslational modification
to the protein. The two different GP genes that we con-
structed yielded similar amounts and types of expression
products in both assay systems (Fig. 1). These findings
indicate that although the noncoding nucleotides (stem-
loop structures) found at the 59 ends of the authentic
EBOV GP mRNAs may have some role in viral replication,
they are unimportant for in vitro expression, at least in
the two systems that we tested. Transient expression of
the EBOV NP yielded an expression product of the pre-
dicted size (Fig. 1).
Immunogenicity of the GP naked DNA vaccine
Our initial studies focused on evaluation of GP as a
candidate vaccine because it is the only major surface
protein of virions and was therefore the most logical
candidate for eliciting neutralizing antibodies. To deter-
mine if the GP DNA was able to elicit protective immunity
in mice, we vaccinated groups of 10 BALB/c mice by
delivering DNA-coated gold beads to the abdominal epi-
dermis by particle bombardment with helium pressure
using the PowderJect-XR gene gun (PowderJect Vac-
cines, Inc. Madison, WI). The first four groups tested
received one, two, three, or four vaccinations of 0.5 mg of
EBOV DNA or control DNA at 4-week intervals. Mice
were challenged with mouse-adapted EBOV 12 weeks
after the single inoculation, 8 weeks after the second of
two inoculations, or 4 weeks after the third or fourth
inoculations. A clear dose response of protection was
observed with increasing numbers of vaccinations, and a
delay in time to death was observed for some of the
vaccinated mice that succumbed to the challenge (Fig.
2). Increasing the number of vaccinations to five with 0.5
mg of DNA did not improve the survival of mice after
challenge.
Because only partial protection was achieved with the
GP doses and regimens tested, we inoculated additional
groups of mice with a priming dose of 0.5 mg of DNA and
increased the dosage of DNA in the second, third, and
fourth boosts to 1.5 mg of DNA. The boosts were given at
4-week intervals and the mice were challenged approx-
imately 8 weeks after the third boost or 4 weeks after the
fourth boost. All mice survived the challenge (Fig. 2).
Survival of mice in each group (Fig. 2) that received two
or more EBOV DNA inoculations was significantly better
than that of control mice (log rank analysis, P values: two
doses 0.0042; three doses 0.0002; four doses 0.0001; five
doses ,0.0001; either group receiving 1.5 mg, ,0.0001).
Survival of mice whose regimen included doses of 1.5 mg
of DNA (Fig. 2) was significantly better than that of mice
that received one, two, three, or five doses of 0.5 mg of
DNA (log rank analysis, P values: one dose ,0.0001; two
doses 0.0041; three doses 0.0289; five doses 0.0117) but
not significantly better than that of mice which received
four doses of 0.5 mg of DNA (P 5 .1246).
To assess the ability of the vaccine to reduce viremia,
a factor that we have found to be predictive of subse-
quent survival, we administered 0.5 mg of EBOV GP DNA
FIG. 2. Survival of mice vaccinated with Ebola GP DNA/gene gun
vaccine and challenged with EBOV. The number of vaccinations and
amount of DNA delivered are indicated to the right of each survival
curve.
FIG. 1. Transient expression of EBOV GP and NP genes. cDNA
representing the coding region of the GP gene (GP1), or the coding
region plus 139 nucleotides of 59 noncoding information (GP2), or the
coding region of the NP gene (NP) were cloned into the plasmid vectors
pCRII and pWRG7077. The pCRII constructs and a control of pCRII with
no insert were assayed for expression in cell cultures infected with a
recombinant vaccinia virus expression T7 polymerase. The pWRG7077
constructs and a control of pWRG7077 with no insert were assayed for
expression in cell cultures infected with a recombinant vaccinia virus
expression T7 polymerase. The pWRG7077 constructs and a control of
pWRG7077 with no insert were assayed for expression in COS cells.
Radiolabeled expression products were immune-precipitated and sep-
arated by gel electrophoresis. The positions of radiolabeled protein
markers (not shown) are indicated to the left of each autoradiograph.
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or control DNA three times to groups of 10 mice. The
mice were challenged 4 weeks after the final vaccination
and were terminally exsanguinated 3 or 5 days after
challenge. Serum viremias were assessed by plaque
assay. Three days after challenge, none of the 4 vacci-
nated mice examined were viremic, while the 4 control
mice all had viremia titers greater than 105 PFU/ml (Fig.
3). At 5 days after challenge, all 5 of the control mice had
viremic titers .108 PFU/ml, while 2 of 6 vaccinated mice
had titers ,103 PFU/ml, and 1 mouse was still aviremic.
The other 3 mice also had lower viremic titers than
control mice (Fig. 3). We did not measure the replication
of virus in organs or tissues other than blood because in
our previous studies we found that levels of viremia
correlated well with viral replication in the target organs,
spleen and liver (Bray et al., 1998; Bray et al., unpub-
lished information).
Three additional groups of mice that received the
same vaccine regimen as those that were examined
for viremia were challenged at 12, 24, or 36 weeks
after the final vaccination to measure the duration of
protective immunity elicited by the GP DNA vaccine.
Seven of 10 mice survived the 12-week challenge, 2 of
9 survived the 24-week challenge, and 5 of 10 survived
the 36-week challenge. Of the 40 control mice chal-
lenged at the four various time points of this study,
mortality was 10/10, 10/10, 9/10, and 9/10. These data
indicate that GP alone can afford complete protective
immunity to EBOV in mice and that partial immunity
lasts for at least 9 months.
In some studies with other DNA vaccines, increas-
ing the time between vaccination improved immuno-
genicity of the vaccine (Fuller et al., 1997). To investi-
gate whether a longer resting time between vaccina-
tions might provide the same benefits as an additional
vaccination, we inoculated groups of 20 mice with 0.5
mg of DNA either three times at 4-week intervals or
two times at a 6-week interval. Four weeks after the
final vaccination, the mice were challenged with EBOV.
Although the prechallenge ELISA titers of mice that
received three vaccinations were higher than those
that received two vaccinations, there was no differ-
ence in the number of survivors (Fig. 4). Therefore, the
longer resting period resulted in comparable protec-
FIG. 3. Viremia of EBOV DNA-inoculated or control mice challenged
with mouse-adapted EBOV. Mice were vaccinated five times with 0.5
mg of EBOV GP DNA at 4-week intervals and then challenged with
mouse-adapted EBOV 4 weeks after the final vaccination. Viremia was
measured at days 3 and 5 postinfection (PI).
FIG. 4. ELISA titers of mice vaccinated with EBOV GP DNA. Mice were vaccinated two times at a 6-week interval (A) or three times at 4-week
intervals (B) by gene gun inoculation of approximately 0.5 mg of DNA. Sera were analyzed by ELISA 4 weeks after the final vaccination at dilutions
of 1.5–3.0 log10. Titers of mice that survived challenge are shown to the left of the dotted lines.
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tion with fewer immunizations. There was apparently
no strong correlation of ELISA antibody titer and sur-
vival, as 2 of the mice with the highest antibody titers
died, and 2 of the mice with the lowest antibody titers
survived (Fig. 4).
Although we did not measure neutralizing antibody
responses for all groups of mice, we did perform plaque
reduction neutralization tests (PRNT50) on pooled sera
from mice that had received one, two, or three doses of
0.5 mg of DNA. For all groups of mice, prechallenge
PRNT50 titers were ,1:20 and postchallenge titers were
1:80. These data are consistent with other studies in
which we found that only low levels of neutralizing anti-
bodies were detected in either control or vaccinated
mice that survive EBOV challenge and resultant disease
(unpublished information).
To determine if the naked DNA, GP vaccine was also
able to elicit cell-mediated immune responses in mice,
0.5 or 1.5 mg of the GP DNA vaccine was administered
from one to five times at 4-week intervals, and cytotoxic
T lymphocytes of individual mice were measured by
chromium release assays after each dose on target cells
expressing EBOV GP. Splenocytes from all seven mice
tested that received at least two vaccinations with 1.5 mg
of DNA demonstrated a range of maximum specific lysis
of 9–40% (Fig. 5). Spleen cells from four of seven mice
that received at least 2 vaccinations with 0.5 mg of DNA
also specifically lysed the target cells (Fig. 5).
FIG. 5. CTL responses of mice vaccinated with EBOV GP DNA. Mice were vaccinated at 4-week intervals by particle bombardment of the epidermis
with approximately 0.5 mg or 1.5 mg of DNA. Spleens were removed approximately 3 weeks after the final inoculation and CTL activity was measured
by chromium release assays. Target cells were transformed P815 mouse cells expressing EBOV GP. Results are shown for individual mice given from
one to five vaccinations with the GP vaccine. Splenocytes from each mouse were also tested against untransformed control P815 cells and
background lysis was less than 5% at E:T ratios for all mice (data not shown). Assays were performed on 2 separate days which are indicated as
A or B in the legends. Specific lysis (% lysis of test mice 2 % lysis of control mice) is shown.
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Comparing EBOV GP and NP candidate vaccines
Although GP alone offered protection from EBOV chal-
lenge, at least four vaccinations were required. For a
human vaccine, it is desirable to elicit immunity with the
lowest possible number of vaccinations. Also, based on
the findings that passive transfer of EBOV immune horse
serum offers only incomplete protection to some nonhu-
man primates (Jahrling et al., 1996) and on studies that
showed only sporadic protection of guinea pigs with
passively transferred neutralizing monoclonal antibodies
to MBGV (A. Schmaljohn, unpublished information), we
decided to test the vaccine potential of an additional
EBOV gene, NP.
To compare the vaccine potential of NP and GP, we
inoculated groups of 14 mice each with approximately
0.5 or 3 mg of each of the two candidate vaccines. The
mice received three vaccinations at 4-week intervals,
and their antibody titers to GP or NP were measured by
ELISA 4 weeks after each vaccination. Antibodies were
detectable after the first inoculation with either vaccine
and rose after each of the two subsequent vaccinations
(Fig. 6A). Ten mice from each group were challenged 4
weeks after the final vaccination. Partial protection was
achieved with both GP and NP vaccines (Fig. 6B) and no
statistically significant difference between the two vac-
cines was found (Breslow statistical analysis). As ob-
served with GP inoculations, higher antibody titers de-
tected by ELISA did not predict better protection.
A preliminary assessment of CTL responses was per-
formed on pooled spleen cells from two mice from each
of the NP groups and from the group that received 3 mg
of GP DNA. The ELISA titers for the mice used in the
chromium release assays were all .1:1000. Target cells
for the NP-immunized mice were transformed P815 cells
expressing NP. Specific lysis of NP and GP targets was
observed (Fig. 7) and, for the small number of samples
tested, appeared to be consistent with the GP data (Fig.
5) suggesting better CTL responses in mice that re-
ceived higher amounts of DNA.
DISCUSSION
The filoviruses, MBGV and EBOV, are among the most
deadly of known human pathogens. Control measures
are impossible because the natural ecology, vector(s),
and mode of transmission are largely unknown. There-
fore, vaccination appears to be the only potential means
FIG. 6. Comparison of antibody responses and survival after challenge of mice vaccinated with the EBOV GP and NP candidate vaccines. (A) ELISA
titers were determined for individual mice after each of three vaccinations with approximately 0.5 or 3 mg of NP or GP DNA, and geometric mean titers
(GMT) were calculated. (B) The mice were challenged with 30 LD50 of mouse-adapted EBOV. Results are shown for the first 15 days, but remained
the same during the rest of the 21-day observation period.
FIG. 7. Comparison of CTL responses of mice vaccinated with NP or
GP DNA. Two mice from each NP group and from the GP group
receiving 3 mg of DNA (shown in Fig. 6A) were selected for CTL assays.
Chromium release assays were performed as described under Mate-
rials and Methods and in the legend to Fig. 5. Targets were transformed
P815 cells expressing EBOV GP or NP. The results shown are for
pooled spleens of the two mice.
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for protecting at-risk individuals from hemorrhagic fever
caused by these viruses. Our studies were intended to
determine if DNA vaccines can provide protection from
EHF in an adult, immunocompetent mouse model. Use of
a mouse model allowed us to measure protection by our
DNA vaccines in statistically significant group sizes and
will facilitate further evaluation of cell-mediated immune
responses. However, it is not yet known whether either of
the rodent models commonly used for filovirus studies
(guinea pigs and mice) accurately mimic human disease;
thus all such studies will require confirmation in nonhu-
man primates.
For our studies, we used a Zaire 1995 strain of EBOV
to generate gene products. Sequence analysis of the GP
and NP genes of this isolate confirmed earlier findings
with the GP gene (Sanchez et al., 1996), which indicated
that the virus which caused the 1995 EHF outbreak in
Zaire was the same virus that caused an outbreak in that
region in 1976. These findings suggest that EBOV is
stably maintained in nature.
Although it is not completely clear what is needed to
afford protective immunity to filovirus infections, it is
likely that both humoral and cell-mediated immune re-
sponses will be required. Passive transfer of neutralizing
antibodies can protect guinea pigs from filovirus infec-
tions (Jahrling et al., 1996; Hevey et al., 1997); thus, in
some animal models, humoral immunity alone is suffi-
cient for protection. However, because filoviruses repli-
cate so quickly and to such high titers, it may not always
be possible to overcome infection without the presence
of a vigorous cell-mediated immune response in addition
to an antibody response. Studies to define the filovirus
antigens best suited for elicitation of protective immune
responses are still in progress. Preliminary experiments
with vaccinia virus recombinants demonstrated that pro-
tection from EBOV challenge could be obtained by im-
munizing guinea pigs with recombinants expressing GP
but not with those expressing NP, VP35, VP40, or sGP
(Gilligan et al., 1997). Similarly, protection from MBGV
challenge could be obtained in guinea pigs immunized
with baculovirus-expressed MBGV GP, but not NP (Hevey
et al., 1997). In more recent studies, MBGV NP expressed
from alphavirus recombinants conferred protective im-
munity to guinea pigs (A. Schmaljohn et al., unpublished
information).
As we were preparing this paper, a study appeared in
which DNA vaccines for EBOV, delivered by intramuscu-
lar injection, were assessed in mice and guinea pigs (Xu
et al., 1998). In that study, nonneutralizing antibody re-
sponses could be elicited in mice by three intramuscular
inoculations of 50 mg of plasmid DNA containing EBOV
NP or GP cDNA. Only mice receiving the GP DNA had
demonstrable CTL responses. Because a guinea pig-
adapted strain of EBOV was used in that study, the mice
were not challenged; thus protection could not be corre-
lated with the observed CTL or antibody responses. In
the same study, guinea pigs given four intramuscular
injections of 100 mg of EBOV GP or NP cDNA at 2-week
intervals were protected from challenge for 10 days
when the challenge was performed 20 days after the
final inoculation. However, when the vaccine was given
two times at 2-week intervals, followed by a boost 4
weeks later and another boost 10 weeks after that, only
the mice that received the GP DNA were protected from
a challenge delivered 10 days after the final boost. Be-
cause the guinea pigs were killed 10 days after chal-
lenge for assay of viral antigen and virus in organs, it was
not possible to determine if delayed deaths due to partial
protection by the vaccine would have occurred at later
times. Assessment of antibody responses by ELISA re-
vealed that antibodies to both NP and GP were gener-
ated but that only GP-immunized guinea pigs were pos-
itive in cell proliferation and T cell growth factor assays.
The authors concluded that cell-mediated but not hu-
moral immune responses correlated with protection;
however, that conclusion does not seem to be supported
by their observation of protection of NP-immunized
guinea pigs in the absence of detectable cell-mediated
immune responses, nor by previous reports that pas-
sively tranferred immune serum can protect guinea pigs
from EBOV and MBGV infection (Jahrling et al., 1996;
Hevey et al., 1997).
In our study, we were able to demonstrate significant
and long-lived protection from EBOV challenge in mice
immunized with very small quantities of the GP DNA.
Consistent with earlier studies (Gilligan et al., 1997),
neutralizing antibody responses to GP were low or un-
detectable before challenge and rose to titers of only
1:40 to 1:80 after challenge. We know that the mouse-
adapted EBOV used for our challenge studies can be
neutralized in such assays by antisera to nonadapted
EBOV (Bray et al., 1998), so our finding is not an artifact
of the mouse model. The finding is also consistent with
other studies in our laboratory, including an attempt to
produce hyperimmune mouse ascitic fluid to EBOV by
priming with non-mouse-adapted EBOV in Freund’s ad-
juvant, followed by repeated large doses of a suckling
mouse brain preparation of mouse-adapted virus in in-
complete Freund’s adjuvant. The resultant ascitic fluid
had a PRNT titer of only 1:40, suggesting that GP was
only weakly immunogenic and that protection is not me-
diated by antibody alone. In this study, we demonstrated
the induction of vigorous CTL responses specific for both
NP and GP, suggesting a potential role for CTL for pro-
tection against EBOV in this mouse model.
In addition to protection by a GP DNA vaccine, we
demonstrated that 3-mg quantities or less of NP DNA can
also elicit protective immunity in mice. No statistically
significant difference in protection between the GP and
NP vaccines was observed. Thus, the gene gun method
of DNA inoculation appears to be an efficient means to
elicit protective immunity to EBOV in mice, and both the
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GP and NP genes show promise as candidate vaccines
capable of eliciting both cellular and humoral immune
responses. Further studies are planned to investigate a
combination GP/NP DNA vaccine, to evaluate the vac-
cines in nonhuman primates, and to examine in more
detail the role of CTL in protection. Clearly, it is also
essential that we further define important parameters for
protective immunity to filoviruses so that we may, if
necessary, redirect our vaccines toward elicitation of the
most appropriate immune response.
MATERIALS AND METHODS
Viruses, cells, and medium
EBOV, strains Zaire 76 (also called Mayinga strain) and
Zaire 95, respectively, were originally isolated from pa-
tients during 1976 and 1995 outbreaks of Ebola hemor-
rhagic fever in Africa (CDC, 1995a,b; Johnson et al., 1977;
Sanchez et al., 1996). To select a variant of EBOV that
was pathogenic for mice, the EBOV (strain Zaire 76) was
serial passaged in progressively older suckling BALB/c
mice, and a ninth-passage isolate which was uniformly
lethal for adult BALB/c mice was plaque-purified (Bray et
al., 1996, 1998). This mouse-adapted EBOV was propa-
gated in Vero E6 cells (ATCC C1008, CRL1586), aliquot-
ted, and used in all mouse-challenge experiments. A
stock of EBOV, strain Zaire 76, which had been passaged
twice in Vero cells, was used in plaque-reduction neu-
tralization assays. Transient expression assays were
performed in baby hamster kidney (BHK) cells or COS
cells. Cells were maintained in Eagle’s minimal essential
medium supplemented with 2% fetal bovine serum and
antibiotics. Virus propagation was performed under bio-
safety level 4 (BSL-4) containment.
P815 mouse cells used for CTL assays were main-
tained in RPMI 1640 (Biowhittaker) containing 10% heat-
inactivated FBS and antibiotics.
Mice
Female BALB/c mice were obtained from the National
Cancer Institute (Frederick, MD). Following DNA immu-
nization and blood sampling, the animals were trans-
ferred to a BSL-4 facility for EBOV challenge. The mice
were then observed on a daily basis for at least 21 days
for signs of illness and mortality. All surviving animals
were euthanized. The investigators adhered to the
‘‘Guide for the Care and Use of Laboratory Animals,’’
prepared by the Committee on Care and Use of Labora-
tory Animals of the Institute of Laboratory Animal Re-
sources, National Research Council (National Institutes
of Health Publication No. 86-23, revised 1985), and used
facilities fully accredited by the American Association for
Accreditation of Laboratory Animal Care.
Cloning and sequence analysis of the GP gene
of EBOV, strain Zaire 95
Total cell monolayers from four 25-cm2 flasks of EBOV-
infected Vero E6 cells were harvested when CPE be-
came evident. Medium was removed from the flasks and
discarded and the infected cell monolayers were lysed
by the addition of 1 ml Trizol reagent (Gibco BRL) to each
flask. The lysates were removed from the BSL-4 labora-
tory for all subsequent manipulations. The samples were
extracted with chloroform, and RNA was precipitated
with isopropanol and recovered by centrifugation. First-
strand cDNA synthesis were performed by using the total
RNA recovered from one of the flasks and a Superscript
cDNA kit (Gibco BRL) according to the manufacturer’s
directions. Primers for RT–PCR were designed based on
the reported sequence of EBOV, strain Zaire 76 (Sanchez
et al., 1996), GenBank Accession Nos. U28077 and
U23187). Two different forward primers were used which
corresponded to nucleotides 5901–5912 or 6037–6054 of
the previously reported sequence and which added a
BglII site to the amplified gene to facilitate cloning. The
forward primers used were 59-gatcagatctGCGATGAA-
GATTAAG-39 or 59-gatcagatctACAATGGGCGTTACAGG-
39, with nucleotides added for cloning purposes listed in
lowercase letters and EBOV-specific nucleotides listed in
uppercase letters. The reverse primer used was 5-gat-
cagatctCTAAAAGACAAATTTG-39. PCR was performed by
using the Expand Long Template PCR System (Boehr-
inger Mannheim). PCR conditions were 1 cycle of 94°C
for 3 min, 42°C for 2 min, and 72°C for 5 min; 15 cycles
of 94°C for 1 min, 42°C for 2 min, and 72°C for 5 min; 10
cycles of 94°C for 1 min, 42°C for 2 min, and 72°C for 7
min; 1 cycle of 94°C for 1 min, 42°C for 2 min, and 72°C
for 10 min. Samples were then held at 4°C until used for
cloning into the pCRII plasmid (Invitrogen). After deter-
mining orientation of the inserts by restriction digestion,
the EBOV GP genes were excised from pCRII by diges-
tion with BglII and were cloned into the BamHI site of
pWRG7077 (Schmaljohn et al., 1997). The nucleotide se-
quences of the cloned genes were determined by using
dideoxy sequencing of 35S-radiolabeled products ac-
cording to the directions included with the Sequenase
DNA sequencing kit (Amersham).
Cloning and sequence analysis of the NP gene
of EBOV
RT–PCR was performed as described above for the GP
gene, except that first-strand cDNA was generated by
using random hexamers, rather than specific primers.
The NP forward and reverse PCR primers, respectively,
were 59-GTATGGATTCTCGTCCTC-39 and 59-CATTCACT-
GATGATGTTGC-3, which correspond to nucleotides 468–
485 and 2674–2692 of the previously reported sequence
of the 1976 isolate of EBOV (Sanchez et al., 1993). The
PCR products were cloned into pCRII plasmid as de-
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scribed above for GP and were then excised by restric-
tion digestion with NotI and BamHI and were ligated to
the same sites in pWRG7077.
Transient expression assays and gel electrophoresis
Expression of EBOV proteins was first measured by
using a transient vaccinia virus/T7 polymerase assay
(Fuerst et al., 1986) and the pCRII construct. The assay
was performed with modifications reported previously
(Iacono-Connors et al., 1996). Briefly, plasmids were
transfected into recombinant vaccinia virus-infected
baby hamster kidney cells (m.o.i. 10) in a six-well cell
culture plate by using Lipofectin reagent (Gibco-BRL).
The cells were radiolabeled from 20 to 24 h postinfection
with 100 mCi/ml of [35S]Promix (methionine and cysteine)
(Amersham) and lysed with a buffer consisting of 10 mM
Tris–HCL, pH 8.0, 1 mM EDTA, 0.5 M NaCl, 4% Zwitter-
gent 3-14 (Calbiochem-Behring), and protease inhibitors
(Boerhringer Mannheim). Cell nuclei were removed by
centrifugation for 5 min at 12,000 g in a microcentrifuge.
An aliquot (100 ml) of each supernatant was mixed with
5 ml of a polyclonal hyperimmune guinea pig serum to
EBOV. After incubation on ice overnight, 100 ml of 50%
Protein A–Sepharose (Sigma) in lysis buffer was added
to each tube, and the samples were shaken at 4°C for 30
min. The Sepharose beads were recovered by centrifu-
gation in a microcentrifuge and were washed three times
with lysis buffer and one time with 10 mM Tris–HCl, pH
8.0. The beads were then boiled for 2 min in protein
sample buffer and analyzed by SDS–polyacrylamide gel
electrophoresis (PAGE) as described previously (Arikawa
et al., 1989).
Transient expression assays of the pWRG7077 con-
structs were performed by transfection of COS cells with
5 mg of each plasmid containing one of the two EBOV GP
genes or with 5 mg of pWRG7077 with no insert as
described previously (Schmaljohn et al., 1997). The cells
were radiolabeled from 24 to 28 h after infection, lysed,
and analyzed by gel electrophoresis as described above.
Preparation of gene gun cartridges, immunization,
and challenge of mice
Plasmid DNA was precipitated onto gold beads as
described previously (Eisenbraun et al., 1993). The gold
beads were approximately 2 mm in diameter and were
mixed with approximately 0.5–1 mg of DNA/mg gold. The
DNA-coated gold particles were dried on the inside walls
of Tefzel tubing, which was then cut into 0.5-in. sections.
Each cartridge contained approximately 0.5 mg of gold
(dry weight) with net loads of 0.25–0.5 mg of DNA (mea-
sured by fluorometric assays of eluted DNA or estimated
by gel electrophoresis and comparison to ethidium bro-
mide-stained standards). The PowderJect-XR gene deliv-
ery device (D. McCabe, inventor. Agracetus, Inc., as-
signee; PCT patent WO 95/19799, July, 27, 1995) was
used to achieve intracellular inoculation of epidermal
cells of BALB/c mice (approximately 6 to 8 weeks old)
with approximately 0.5–1 mg of DNA (Pertmer et al.,
1995). Blood samples were collected from the retroorbital
sinuses of the mice at various times after vaccination.
For challenge studies, the mice were transferred to a
BSL-4 containment area and inoculated IP with approx-
imately 30 times the amount of mouse-adapted EBOV
previously determined to cause death in 50% of adult
BALB/c mice (30 LD50). This dose equaled 1 plaque-
forming unit on Vero E6 cells and 30 virions as measured
by electron microscopy. Mice were observed daily for
signs of illness and for death. In one experiment, groups
of 10 ear-tagged vaccinated or naive mice were chal-
lenged with virus, and the first 4 mice from each group
were terminally exsanguinated on day 3 postinfection. All
surviving mice were terminally exsanguinated on day 5
(6 vaccinated and 5 naive control mice).
Plaque assay and plaque reduction neutralization test
(PRNT50)
To quantitate viral infectivity, virus stocks or whole
blood samples from mice were serially diluted in growth
medium and then were allowed to adsorb to confluent
Vero E6 cells in 12-well cell culture plates for 1 h at 37°C.
The cells were overlaid with agarose diluted in cell
culture medium and incubated at 37°C for 6 more days
(Bray et al., 1998). A 1:5000 dilution of neutral red in
buffered saline solution was then added to the wells and
plaques were counted the following day.
To measure neutralizing antibodies, aliquots of EBOV
in growth medium were mixed with serial dilutions of
pre- or postchallenge mouse sera and incubated at 34°C
for 1 h. The mixture was used to infect Vero E6 cells, an
agarose overlay was applied, and plaques were counted
1 week later. Controls consisted of virus mixed with
serial dilutions of a high-titer anti-EBOV serum, or with
normal serum, or with medium only. The neutralizing
antibody titer was calculated as the reciprocal of the
highest dilution of serum which caused a 50% reduction
in the number of plaques compared to the normal serum
control.
ELISA
To prepare antigen for ELISA, EBOV was purified and
inactivated as described previously for MBGV (Hevey et
al., 1997). Briefly, supernatants from EBOV-infected cul-
tures of Vero E6 cells were concentrated by polyethylene
glycol precipitation. The PEG precipitates were resus-
pended in buffer and separated by centrifugation in con-
tinuous 20–60% sucrose gradients for 4 h at 38,000 rpm
in a SW41 rotor (Sorvall). The purified virus was inacti-
vated by irradiation (6 MR, 60Co source) and tested for
the absence of infectivity in cell culture before use.
ELISA was performed essentially as described previ-
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ously (Hevey et al., 1997). Briefly, 96-well polyvinylchlo-
ride (PVC) microtiter plates (Dynatech, Vienna, VA) or
high-binding RIA/EIA flat-bottom plates (Costar) were
coated with 50 ml/well of antigen at a predetermined
optimal dilution (1:500 or 1:1000) in PBS. Plates were
incubated at 4°C overnight and then nonspecific binding
was blocked by the addition of 200 ml/well of 5% pow-
dered nonfat milk in PBS containing 0.02% Tween 20.
Test antibodies were diluted in either half-log or fivefold
increments. Secondary antibody was horseradish perox-
idase (HRPO)-labeled goat anti-mouse IgG antibody
(Kirkegaard and Perry Laboratories) and the detector
substrates were either 2,29-azino-di 3-ethybenthiazoline
sulfonate (ABTS; Kirkegaard and Perry) or 3,39,5,59,-tetra-
methylbenzidine (TMB, Kirkegarrd and Perry Laborato-
ries). Values were read at 405 nm (ABTS) or 450 nm
(TMB). Endpoint titers were defined as OD values .0.2
above the mean OD value obtained with the same dilu-
tion of serum from control mice.
Transformation and selection of P815 cells
To prepare target cells for chromium release assays,
EBOV NP or GP cDNA was cloned into the plasmid
vector pCDNA 3.1 (Invitrogen), and the plasmids were
used to transform P815 mouse cells. For the GP cell line,
approximately 0.5 mg of DNA was introduced into the
cells by gene gun inoculation of approximately 300,000
cells suspended in 20 ml of RPMI 1640 medium. For the
NP cell line, 5 mg of DNA and 25 ml of Lipofectamine
(Gibco-BRL) were used to transfect was used to transfect
cells approximately 106 cells in 0.8 ml of OptiMEM
(Gibco-BRL) according to the directions accompanying
the Lipofectamine reagent. After incubation in transfec-
tion medium for 8 to 24 h, the medium was replaced with
RPMI 1640 containing 10% FBS and 0.3 to 1 mg/ml G418
(Geneticin, Gibco BRL). Cells were incubated for 3 to 5
days, or until control cells had all died and colonies of
transformed cells appeared. The transformed cells were
then trypsinized and cloned by serial dilution in RPMI
plus G418 in 96-well microtiter plates. Wells were ob-
served for the presence of single colonies and when
cells became confluent, were transferred to T25 flasks.
Numerous clones were screened with a FACS analyzer
after incubation with specific mouse monoclonal anti-
bodies to EBOV NP or GP and with fluorescein-tagged
anti-mouse antibodies. Cell clones displaying the great-
est fluorescence were further cultured for use as CTL
targets.
Chromium release assays
Assays for CTL activity were performed essentially as
described previously (Pertmer et al., 1995). Briefly, mice
were killed 3 weeks after the final immunization. Spleens
were minced in 5 ml of RPMI 1 10% FBS, after which they
were applied to cell strainers (Falcon, Cat. No. 2350) and
collected in 50-ml conical tubes. Red blood cells were
lysed by the addition of ACK lysis buffer (Quality Biologi-
cals, Gaithersburg, MD) and the splenocytes recovered
by centrifugation. For in vitro stimulation of the spleno-
cytes, 4 3 105 P815 cells (controls) or P815 cells trans-
formed to express EBOV NP or GP were treated with 0.1
mg/ml of mitomycin C and were then incubated with 6 3
106 splenocytes per well in 24-well plates in medium
containing 10 units/ml rat interleukin-2 (Collaborative Re-
search) for 5 to 7 days. Following stimulation, the spleno-
cytes (effector cells) were collected and plated into 96-
well plates at various ratios relative to 40,0000 target
cells radiolabeled with 51Cr for 5 to 7 h. Supernatants
were collected and counted by using an LKB gamma
counter or a Beckman Top Count Instrument. Maximum
release was obtained by lysis of control wells with 2%
Triton 3 100 in PBS. Spontaneous release was deter-
mined from target wells to which only medium was
added. Lysis was calculated according to the formula: %
Lysis 5 100% 3 [average CPM (from duplicate test,
naive, or control wells) 2 average CPM for spontaneous
release wells]/Average CPM for maximum release wells.
Specific lysis was defined as the percentage lysis cal-
culated as above minus the percentage lysis obtained
with lymphocytes from mice immunized with an irrele-
vant plasmid DNA.
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